Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.75 |
| ▸ | CA1 | P00915 | 4/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6947583 | 1.00 | CA2 (0.75) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL28806599 | 0.98 | CA2 (0.72) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL2369450 | 0.95 | CA2 (0.82) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL3856960 | 0.93 | CA2 (0.65) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL4151185 | 0.93 | CA2 (0.65) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL3023637 | 0.93 | CA2 (0.78) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL7638666 | 0.93 | CA2 (0.78) | CA2CA1MAPK1SLC1A2SLC1A1 | |
| SCHEMBL1672036 | 0.91 | CA2 (0.63) | CA2CA1SLC1A2SLC1A1CHRM1 | |
| SCHEMBL7209672 | 0.91 | CA2 (0.63) | CA2CA1SLC1A2SLC1A1CHRM1 | |
| SCHEMBL3861238 | 0.91 | CA2 (0.63) | CA2CA1SLC1A2SLC1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117794896-A | Protease inhibitors for the treatment of coronavirus infections | 斯克里普斯研究学院 | 2024-03-29 | — | — | CN | claimed |
| CN-116648451-A | Antagonist compounds | 阿道尔克斯治疗有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | claimed |
| EP-1622569-A4 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2008-08-27 | — | — | EP | claimed |
| CN-1863532-A | Azaspiroalkane derivatives as metalloproteinase inhibitors | INCYTE COPORATION (US) | 2006-11-15 | — | — | CN | claimed |
| EP-1622569-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Corporation (US) | 2006-02-08 | — | — | EP | claimed |
| EP-1562575-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | Abbott Laboratories (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2004096139-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | claimed |
| EP-0383635-A2 | Peptides having renin inhibitory activity their preparation and use | Sankyo Company Limited (JP) | 1990-08-22 | — | — | EP | claimed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| CN-112423746-B | Novel antimycobacterial heterocyclic amides | 克莱斯通公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024082872-A1 | PAK4 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 成都海博为药业有限公司 | 2024-04-25 | — | — | WO | disclosed |
| CN-117897382-A | Nitrogen-containing tricyclic compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2024-04-16 | — | — | CN | disclosed |
| WO-2004037241-A1 | FUSED CYCLOALKYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF I.A. EPILEPSY | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | THOMPSON LORIN A (US) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1268454-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | Bristol-Myers Squibb Pharma Company (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074796-A1 | SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CA2 3803/4885CA1 3920/4885MAPK1 1860/4885 |
| US-20030232985-A1 | Succinoylamino heterocycles as inhibitors of a beta protein production | APP, BACE1, APH1A | CA2 2594/4885CA1 1679/4885MAPK1 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.